Our research in immunology
At Bristol Myers Squibb, we are working to deliver meaningful solutions that address unmet needs in rheumatology, pulmonology, and dermatology. We have spent the last two decades pioneering new treatments and continually innovating to modulate the body’s immune response to treat disease. Our research aims to address the root cause of disease by controlling inflammation, resetting the immune system and promoting immune homeostasis with the goal of achieving transformational efficacy, durable remissions and functional cures.
Featured in immunology
Intended for healthcare professionals, scientific audiences and media.
Our goal is to restore some of what immune-mediated diseases have taken away — empowering patients and their loved ones to take back their lives.
As part of our vision to transform patients' lives through science, BMS is committed to developing transformational therapies with the potential for durable remission for patients with immune-mediated diseases.
Our sequential immunotherapy framework
As proven pioneers in modulating the body’s immune response, Bristol Myers Squibb continues to pursue pathbreaking science by pushing the boundaries in immune-mediated diseases. Our sequential immunotherapy framework aims to address the root cause of disease by controlling inflammation, resetting the immune system and maintaining the renewed homeostasis – a balancing act akin to leveling out a tipping scale – fueled by a passion to deliver transformational benefits for patients in need.
Our immunology focus areas
Rheumatology at BMS
Over 20 years ago, we pioneered the science of modulating the body’s immune response to treat disease, beginning with our research in rheumatoid arthritis (RA). Building on that foundation, we continue to pursue pathbreaking science across rheumatic diseases including RA, psoriatic arthritis, lupus and Sjögren’s disease. Fueled by the possibility to help more patients, we are following the science to tailor therapies to individual needs, improve outcomes and expand treatment options.
Scientific and disease-state resources
Explore the role of TYK2 pathways in immune signaling and their potential involvement in rheumatic diseases like psoriatic arthritis and lupus.
Explore our stories
Pulmonology at BMS
We are committed to applying our expertise regarding the role of fibrosis in the development of several immune-mediated diseases to advance new treatments that go beyond symptom relief and address the underlying cause of diseases such as pulmonary fibrosis and other pulmonary diseases.
Scientific and disease-state resources
Explore our stories
Dermatology at BMS
Estimated to impact hundreds of millions worldwide, the burden of living with immune-mediated dermatologic diseases runs more than skin deep. Systemic in nature, these diseases are often painful and associated with comorbidities that can reduce life expectancy. No patient deserves to settle. At Bristol Myers Squibb, we are leveraging the power of science that may yield transformational results for patients.
Scientific and disease-state resources
Explore our stories
Explore our scientific resources
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. As global citizens, we work sustainably and responsibly to create a positive impact in the communities where we live and work.